Implants with controlled drug delivery features and methods of using same

• US 9,603,738 B2
• Filed: 03/10/2014
• Issued: 03/28/2017
• Est. Priority Date: 03/15/2013
• Status: Active Grant

• Current Assignee: DOSE Medical Corporation (Glaukos Corporation)
• Original Assignee: DOSE Medical Corporation (Glaukos Corporation)
• Inventors: Haffner, David S., Burns, Thomas W., Heitzmann, Harold A., Curry, Kenneth M.
• Primary Examiner(s): Deak, Leslie
• Application Number:
  US14/776,666
• Publication Number:
  US 20160045363A1
• Time in Patent Office: 1,114 Days
• US Class Current: 1/1
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002

Abstract

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more, drugs and may also Include structures which allow for treatment of Increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Claims

1. A drug delivery ocular implant comprising:

an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen;

at least a first active drug positioned within said interior lumen;

a cap configured for reversible interaction with the proximal end of said outer shell,

wherein said cap comprises at least one aperture;

a membrane positioned between said cap and said proximal end of said outer shell,

wherein said membrane is permeable to said at least a first active drug,

wherein said membrane is dimensioned based on the permeability of said membrane to said at least a first active drug and the desired duration of elution of said first active drug,

wherein upon placement of the cap over the proximal end of the outer shell, said membrane is retained between said cap and said proximal end,

wherein said membrane occludes said at least one aperture, thereby allowing elution of said at least a first active drug to occur only through said membrane;

at least one fluid inflow pathway and one fluid outflow pathway positioned adjacent the distal end of said outer shell,

wherein said at least one fluid inflow pathway and one fluid outflow pathway are configured to deliver ocular fluid to a physiological outflow pathway; and

a retention protrusion on the distal end of said outer shell, wherein said retention protrusion is configured to anchor the ocular implant at a target tissue site.

2. The implant of claim 1, wherein said membrane has a thickness of between about 50 and about 100 microns.

3. The implant of claim 2, wherein said at least a first active drug elutes from said ocular implant for a period of time ranging from about 12 to about 24 months.

4. The implant of claim 1, wherein said membrane has a thickness of between about 90 and about 200 microns.

5. The implant of claim 4, wherein said at least a first active drug elutes from said ocular implant for a period of time ranging from about 24 to about 48 months.

6. The implant of claim 1, further comprising a distally-positioned seal limiting fluid communication between the interior lumen and an ocular space in which the implant is positioned to that occurring through the membrane.

7. The implant of claim 1, wherein said physiological outflow pathway is Schlemm'"'"'s Canal.

8. The implant of claim 1, wherein said at least one first active drug comprises a prostaglandin, a prostaglandin analog, a prostaglandin inhibitor, and/or combinations thereof.